CN1186473A - 二丙酸氯地米松计定剂量吸入器 - Google Patents
二丙酸氯地米松计定剂量吸入器 Download PDFInfo
- Publication number
- CN1186473A CN1186473A CN96194409A CN96194409A CN1186473A CN 1186473 A CN1186473 A CN 1186473A CN 96194409 A CN96194409 A CN 96194409A CN 96194409 A CN96194409 A CN 96194409A CN 1186473 A CN1186473 A CN 1186473A
- Authority
- CN
- China
- Prior art keywords
- inhaler
- fluorocarbon
- pharmaceutical preparation
- propellant
- beclomethasone dipropionate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 title claims abstract description 28
- 229950000210 beclometasone dipropionate Drugs 0.000 title claims abstract description 23
- 229940071648 metered dose inhaler Drugs 0.000 title claims abstract description 11
- 229920002313 fluoropolymer Polymers 0.000 claims abstract description 38
- 239000003380 propellant Substances 0.000 claims abstract description 34
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 15
- 239000013543 active substance Substances 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 15
- 239000006184 cosolvent Substances 0.000 claims description 13
- 229940038482 beclomethasone dipropionate monohydrate Drugs 0.000 claims description 12
- 229910052782 aluminium Inorganic materials 0.000 claims description 9
- 239000004411 aluminium Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000004695 Polyether sulfone Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 229920006393 polyether sulfone Polymers 0.000 claims description 7
- 210000003928 nasal cavity Anatomy 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 229960002052 salbutamol Drugs 0.000 claims description 5
- JRHNUZCXXOTJCA-UHFFFAOYSA-N 1-fluoropropane Chemical compound CCCF JRHNUZCXXOTJCA-UHFFFAOYSA-N 0.000 claims description 4
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000956 alloy Substances 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 238000007599 discharging Methods 0.000 claims description 4
- 150000004682 monohydrates Chemical class 0.000 claims description 4
- 210000000214 mouth Anatomy 0.000 claims description 4
- 229960004017 salmeterol Drugs 0.000 claims description 4
- 229910045601 alloy Inorganic materials 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims 1
- 239000012453 solvate Substances 0.000 abstract description 2
- 239000013583 drug formulation Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 description 37
- 239000003814 drug Substances 0.000 description 36
- 239000011248 coating agent Substances 0.000 description 34
- 239000000725 suspension Substances 0.000 description 21
- 229940079593 drug Drugs 0.000 description 16
- 238000005507 spraying Methods 0.000 description 11
- 239000000443 aerosol Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000007921 spray Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- -1 for example Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 6
- 229910000838 Al alloy Inorganic materials 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940092705 beclomethasone Drugs 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229940060037 fluorine Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- JLIDBLDQVAYHNE-YKALOCIXSA-N (+)-Abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- RIWRBSMFKVOJMN-UHFFFAOYSA-N 2-methyl-1-phenylpropan-2-ol Chemical compound CC(C)(O)CC1=CC=CC=C1 RIWRBSMFKVOJMN-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229920001780 ECTFE Polymers 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 229920006360 Hostaflon Polymers 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 241001490312 Lithops pseudotruncatella Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 229920006367 Neoflon Polymers 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 229920006361 Polyflon Polymers 0.000 description 1
- 239000004734 Polyphenylene sulfide Substances 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920006355 Tefzel Polymers 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- DXEXNWDGDYUITL-FXSSSKFRSA-N Tipredane Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](SC)(SCC)[C@@]1(C)C[C@@H]2O DXEXNWDGDYUITL-FXSSSKFRSA-N 0.000 description 1
- PRPAGESBURMWTI-UHFFFAOYSA-N [C].[F] Chemical compound [C].[F] PRPAGESBURMWTI-UHFFFAOYSA-N 0.000 description 1
- LMYMBVLOZKGWBR-UHFFFAOYSA-N [C].[F].[Cl] Chemical compound [C].[F].[Cl] LMYMBVLOZKGWBR-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000003373 anti-fouling effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- IWLBIFVMPLUHLK-UHFFFAOYSA-N azane;formaldehyde Chemical compound N.O=C IWLBIFVMPLUHLK-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940098032 beconase Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003821 choline theophyllinate Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 238000009503 electrostatic coating Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- QHSJIZLJUFMIFP-UHFFFAOYSA-N ethene;1,1,2,2-tetrafluoroethene Chemical compound C=C.FC(F)=C(F)F QHSJIZLJUFMIFP-UHFFFAOYSA-N 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229940105623 neo-synephrine Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000069 polyphenylene sulfide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229950001669 tipredane Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
- B65D83/44—Valves specially adapted therefor; Regulating devices
- B65D83/52—Valves specially adapted therefor; Regulating devices for metering
- B65D83/54—Metering valves ; Metering valve assemblies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
- B65D83/75—Aerosol containers not provided for in groups B65D83/16 - B65D83/74
- B65D83/752—Aerosol containers not provided for in groups B65D83/16 - B65D83/74 characterised by the use of specific products or propellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0222—Materials for reducing friction
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mechanical Engineering (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
一种计定剂量吸入器,其部分或全部内表面用一种或多种碳氟聚合物,任意地与一种或多种无氟碳聚合物共同涂敷,用来施放一种吸入药物制剂,其中包括二丙酸氯地米松或者它的一种生理可接受的溶剂化物,一种碳氟化合物抛射剂,任意地与一种或多种其它药理活性剂或者一种或多种赋形剂共同混合。
Description
发明背景
治疗有关呼吸及鼻腔不适的药物常常配制成气雾剂通过口腔,鼻腔给药。一种广泛采用的配制这样的气雾剂药物的方法包括配制一种充分破碎的药物粉末与一种称为抛射剂的液化气体的混悬液。混悬液装在密封容器中,容器可以承受维持抛射剂呈液态所需的压力。混悬液通过触发与容器相配用的定量阀被施放出去。
定量阀可以被设计为每次触发始终喷出固定量的、预先设定的药物制剂。当混悬液被抛射剂的高蒸气压从容器中通过定剂量阀射出时,抛射剂迅速气化,留下所配制药物的非常微小的粒子形成的迅速移动的云。粒子云通过一种引导装置例如一个圆筒或一个底部开口的圆锥体直接被病人吸入鼻腔或口腔中。与气雾剂定量阀触发同时,病人将药物粒子吸入肺或鼻腔中。这种给药系统叫做“计定剂量吸入器”(MDI’S)。关于这种治疗方式的总体背景,可参见Peter Byron,Respiratory DrugDelivery CRC Press,Boca Raton,FL(1990)。
身体衰弱以及在某些情况下,甚至有生命危险的病人经常依赖MDI’S传送药物来迅速缓解呼吸疾病。所以前述传送给病人的气雾剂药物剂量必须与制造商确认的说明书相一致并符合FDA及其它管理机构的要求。即容器中的每个剂量必须在相近的公差范围内是一致的。
一些气雾剂药物有附着于内表面的倾向,即MDI容器、阀门和阀盖的壁。这会导致病人每次触发MDI所得到的药物的量显著低于处方药量。对于氢氟烷烃(也简称为“碳氟化合物”抛射剂系统,例如,P134a和P227,近年发展起来用以取代碳氯氟化合物如P11,P114与P12),这个问题尤其严重。
我们发现,当MDI’s容器内壁用一种氟碳聚合物涂覆时,药物在容器壁的吸附与沉着可显著减少或者基本消除,这样就保证了MDI以气雾剂形式传送药物的一致性。
发明概述
一种定剂量吸入器的部分或全部金属内表面用一种或多种氟碳聚合物、任意地配入一种或多种非氟碳聚合物进行涂敷,用来施放一种吸入药物制剂,该制剂中包括二丙酸氯地米松(beclomethasonedipropionate)或者它的一种生理可接受的溶剂化物,一种碳氟化合物抛射剂,任意地配入一种或多种其它药理活性剂或者一种或多种赋形剂。发明详述
“定剂量吸入器”或者“MDI”有一种装置包括一个容器,一个盖住容器口的弯边的盖,一个装在缩口盖上的药物定量阀。“MDI系统”还带有一个配用的引导装置。“MDI容器”是一个不带有阀门和阀盖的容器。“药物定量阀”或者“MDI阀门”是一个阀门及其相关结构,使MDI每次触发射出依照药物处方预定的药量。引导装置可以包括,例如,一个阀门的触发装置和一个筒形物或者类圆锥形通道,通过它药物制剂可以由充满的MDI容器经由MDI阀门射入病人的口腔、鼻腔中、例如,一个喇叭状触发器。典型的MDI各部件相关性示于美国专利5,261,538,在此引入作为作为参考。
U.S.专利号3,312,590,在此引入作为参考,介绍一种甾体抗炎化合物,其化学名称为9-氯-11D,17,21-三羟基-16fi-甲基孕甾-1,4-二烯-3,20-二酮17,21-二丙酸酯,正式品名为“二丙酸氯地米松”。二丙酸氯地米松气雾剂已被药学组织接受做为治疗哮喘的有效药物并以商标“Beclovent”,“Becotide”和“Beconase”被投放市场。
“药物制剂”是二丙酸氯地米松(或它的一种生理可接受溶剂化物)任意地与一种或多种其它药理活性剂例如其它抗炎药物,镇痛剂或者其它呼吸系统药物共同混合,任意地包含一种或多种赋形剂。此处的“赋形剂”是一种几乎或完全没有药物活性的化学试剂(对所用的量)但是可以改善药物制剂或MDI系统的性能。例如,赋形剂包括但并不仅仅局限表面活性剂,防腐剂,调味剂,抗氧化剂、粘合剂,及共溶剂,例如,乙醇和乙醚。
适用的表面活性剂可由文献中查知,例如,欧洲专利申请号0327777中公布的表面活性剂。适合的表面活性剂用量为药物重量的0.0001%~50%重量比,特别是0.05~5%重量比。一种特别有用的表面活性剂是1,2-二[7-(F-己基)己酰]-丙三基(glycero)-3-二氧磷基-N,N,N-三甲基乙醇胺,也叫做3,5,9-三氧杂-4-磷杂二十二烷基-1-铵,17,17,18,18,19,19,20,20,21,21,22,22,22-十三氟-7-[(8,8,9,9,10,10,11,11,12,12,13,13,13-十三氟-1-氧代十三烷基)氧]-4-羟基-N,N,N-三甲基-10-氧代-4-氧化物,内盐。
一种常用的共溶剂例如C2-6脂肪醇和多元醇如乙醇、异丙醇如丙二醇并优选的是乙醇,可以所需量包括在药物制剂中,或者作为单一的赋形剂或者与其它赋形剂例如表面活性剂一起使用。药物制剂中可适当地包括一种极性共溶剂其占所用抛射剂量的0.01~5%w/w例如乙醇,优选的是0.1~5%w/w例如0.1~1%w/w。
本领域技术人员可以理解,本发明所用的药物制剂,如果合适,可以包括二丙酸氯地米松(或它的一种生理可接受溶剂化物)与一种或多种其它药理活性剂共同混合。这样的药物可以从任何适用于吸入治疗方式的药物中选取。适用的药物可以这样选自,例如,镇痛剂,例如,可待因、二氢吗啡,麦角铵,芬太尼或吗啡;抗心绞痛药物,例如,地尔硫;抗过敏药;例如,色甘酸钠,酮替芬或里多酸;抗感染药;例如,头孢菌素,青霉素,链霉素,磺胺类药物,四环素和戊双眯;抗组织胺药,例如,吡噻胺,抗炎药,例如,fluticasone(例如丙酸盐、脂)氟乐松,丁地去炎松,tipredane或去炎舒松;镇咳药,例如,那可丁;支气管扩张剂,例如,沙丁胺醇,沙美特罗,麻黄碱,肾上腺素,非诺特罗,福摩特罗,异丙肾上腺素,奥西那林,去氧肾上腺素,苄基丙醇铵,pirbuterol,瑞普特罗,利米特罗,叔丁喘宁,isoetharine,妥布特罗,奥西那林或(-)-4-氨基-3,5-二氯-α-[[[6-[2-(2-吡啶基)乙氧基]己基]氨基]甲基]苯甲醇;利尿药,例如,阿米洛利;抗胆碱药,例如,ipratropium,阿托品或奥美铵;激素类药物,例如,可的松,氢化可的松或氢化泼尼松;黄嘌呤类药物,例如氨茶碱,胆茶碱,赖氨酸茶碱或茶碱;和治疗用蛋白质和多肽,例如,胰岛素或高血糖素。
本领域的技术人员会很清楚,如果合适,这些药物可以其盐(例如碱金属盐或铵盐或者酸加成盐)或者以其酯(例如低级烷基酯)或者其溶剂化合物(例如水合物)形式使用,以便使药物活性和/或者药物稳定性最佳化和/或者使药物在抛射剂中的溶解度降至到最低。
特别优选的药物制剂包括二丙酸氯地米松(或者它的一种生理可接受溶剂化物)与一种支气管扩张剂例如舒喘灵(例如用作游离碱或者硫酸盐)或者沙美特罗(例如用作黄嘌呤盐)共同混合。
此处所指“抛射剂”是一种药理上的惰性液体,它的沸点从大约室温(25℃) ~大约-25℃,室温状态下,抛射剂单独或共同混合呈高蒸气压状态。MDI系统触发时,WDI中的抛射剂所形成的高气压使药物制剂的一定量从定剂量阀射出,然后抛射剂迅速气化使药物粒子分散。本发明所用的抛射剂是低佛点碳氟化合物;特别是1,1,1,2-四氟乙烷,又名“抛射剂134a”或者“P134a”和1,1,1,2,3,3,3-七氟丙烷,又名“抛射剂227”或者“P227”。
本发明中所用的药物制剂可以不含有或者基本上不含有药物赋形剂例如表面活性剂和共溶剂等。这样的药物制剂是有好处的,因为和含有赋形剂的药物制剂相比,它们基本上没有味道和气味,更少刺激性和毒性。这样,一个优选的药物制剂基本上包括二丙酸氯地米松(或者其一种生理可接受的溶剂化物)、任意地与一种或多种其它药理活性剂特别是舒喘灵(或者其一种生理可接受盐)和一种碳氟化合物抛射剂共同混合。优选的抛射剂是1,1,1,2-四氟乙烷,1,1,1,2,3,3,3-七氟-n-丙烷或者它们的混合物,特别是1,1,1,2-四氟乙烷。
最常用的MDI容器和阀盖是由铝或者一种铝合金制成的,但是也可采用不受药物制剂影响的其它金属,例如不锈钢,一种铜合金,或者锡板。MDI容器也可由玻璃或塑料制成。但是本发明中优选的MDI容器是由铝或其一种铝合金制成的。增强铝或者铝合金材料的MDI容器是有利的。这种增强的MDI容器可以耐受特殊压力的涂敷与固化条件,例如,某种碳氟聚合物所需的特殊高温。高温下致畸倾向减弱的增强MDI容器包括含有侧壁和一种加厚的底的MDI容器和含有基本呈椭圆形的底(它增加了容器侧壁和底的角度)、而不是标准MDI容器的半球形底的MDI容器。具有椭圆形底的MDI容器给涂敷提供了更多的便利条件。
构成药物定量阀的部件通常由不锈钢,一种无药理活性和耐受抛射剂的聚合物,例如缩醛、聚酰胺(例如,Nylon),聚碳酸脂,聚脂,碳氟聚合物(例如,Teflon)或者这些物质的混合物制成的。另外,阀门中或周围装有由各种材料(例如丁腈橡胶,聚氨基甲酸乙酯,乙酰树脂碳氟聚合物)制成的密封圈和“O”形环,或者其它弹性材料。
本发明中所用的碳氟聚合物包括由一种或多种以下单体聚合的碳氟聚合物多倍体,单体包括:四氟乙烯(PTFE),氟代乙烯基丙烯(FEP),全氟烷氧基烷烃(PFA),乙烯基四氟乙烯(ETFE),氟化亚乙烯(PVDF),和氯化乙烯基四氟乙烯。优选的氟代聚合物有着相对高的氟碳比,例如全碳氟聚合物例如PTFE,PFA,和FEP。
氟代聚合物可与无氟聚合物掺配,例如聚酰胺,聚亚酰胺,聚醚砜,聚苯硫化物和氨甲醛热固性树脂。这些添加的聚合物增强了涂敷于容器壁的聚合物的粘着力。优选的聚合物掺配物是PTFE/FEP/聚酰胺酰亚胺,PTFE/聚醚砜(PES)和FEP-苯并胍胺。
特别优选的涂料是纯的PFA,FEP和PTFE与聚醚砜(PES)的掺配物。
碳氟聚合物的市场流通商标是例如Teflon,Tefzel,Halar,Hostaflon,Polyflon,和Neoflon。聚合物的类别包括FEP DuPont856-200,PFA DuPont 857-200,PTFE-PES DuPont 3200-100,PTFE-FEP聚酰胺酰亚胺DuPont 856 P23485,FEP粉末DuPont 532和PFA Hoechst6900n。涂层的厚度是大约1μm-大约1mm。适合的涂层厚度是大约1μm~大约100μm,例如1μm~25μm。涂层可以采用一层或多层涂敷。
用于本发明中的碳氟聚合物优选地涂敷在金属制的MDI容器上,尤其是铝制或其一种合金所制的MDI容器。
特制的(例如微粉化的)药物的粒径应使基本上所有的药物依照气雾剂的给药方法被吸入肺中,这样药物的粒径应小于100μm,理想的应小于几个μm,尤其是,在1~10μm之间,例如1~5μm。
最后的气雾剂制剂中的药物相对于制剂总量的比理想地为0.005~10%的重量比,特别是0.005~5%的重量比,尤其是0.01~1.0%的重量比。
本发明的另一方面是定剂量吸入器,其部分或全部金属内表面用一种或多种碳氟聚合物。任意地与一种或多种氟聚合物共同涂敷,用来分散一种吸入药物制剂,制剂包括二丙酸氯地米松和一种碳氟化合物抛射剂、任意地与一种或多种其它药理活性剂和一种或多种赋形剂混合。
本发明中的定剂量吸入器中所用的一种特殊的制剂包括:
(a)二丙酸氯地米松一水合物,所有一水合物的粒径基本上小于
20μm;
(b)除该一水合物的结晶水的水分外制剂至少含占制剂重量
0.015%的水分和
(c)一种碳氟化合物抛射剂。
这样气雾剂制剂理想地含有至少占制剂重量0.015%(例如,0.015~0.1%)的水分(除去二丙酸氯地米松一水合物所带结晶水的水分外),优选地至少为0.02%,例如占重量0.025%或更多的水分。本发明中优选的制剂中,除二丙酸氯地米松一水合物所带结晶水的水分外,含有至少0.026%,例如占重量0.026~0.08%的水分。任意地,制剂中可含有适当量的共溶剂例如乙醇。制剂中可适当地含有占抛射剂0.05%~3.0%w/w的一种常用的共溶剂例如乙醇。优选的碳氟化合物抛射剂是1,1,1,2-四氟乙烷,1,1,1,2,3,3,3-七氟-n-丙烷或者它们的混合物,尤其是1,1,1,2-四氟乙烷。
用于本发明中的更进一步的药物制剂中不含有或基本上不含有表面活性剂。这样,更进一步的不含有表面活性剂的制剂中包括或基本上由二丙酸氯地米松或者其一种生理上可接受的溶剂化物,任意地与一种或多种其它的药理活性剂结合使用,一种碳氟化合物抛射剂和占抛射剂0.01~0.05%w/w的一种极性共溶剂例如乙醇共同混合。优选的抛射剂是1,1,1,2-四氟乙烷或者,1,1,1,2,3,3,3-七氟-n-丙烷,尽管也可使用它们的混合物。
本发明的更进一方面是MDI,其部分或基本上全部内表面例如金属表面具有PFA或者FEP,或者掺配的碳氟聚合物树脂系统例如PTFE-PES涂层,带有或者不带有聚酰胺酰亚胺或者聚醚砜的适当涂层,用来施放上述提及的药物制剂。优选的MDI容器是由铝或其一种合金制成的。
MDI容器可依照金属涂敷领域的方法来涂敷。例如,一种金属,例如铝或不锈钢,在被压制或拉伸成容器状之前,可以先被预涂成盘管(筒)料并熟化。这种方法适用于大量生产,原因有二。首先,盘管料涂敷领域已十分发达并有数家制造商可以提供高标准均匀性的金属旋管料并有着很广的厚度范围。其次,预涂料可以基本上按照与未涂料的压制或拉伸方法一样的方法,在高速和高精密条件下被压制或拉伸。
可得到涂敷容器的其它技术有干燥粉末静电涂敷或者用涂敷用氟代聚合物/聚合物掺配物的配方来喷涂预制的MDI容器内部然后固化。也可将预制的MDI容器浸入碳氟聚合物/聚合物掺配物涂敷配方中然后固化,这样变成内部和外部的涂敷。碳氟聚合物/聚合物掺配物配方也可被灌入MDI容器内然后沥出,使内部涂有聚合物。考虑到生产上的便利性,预制的MDI容器可简便地用氟代聚合物/聚合物掺配物喷涂。
碳氟聚合物/聚合物掺配物也可用碳氟化合物单体等离子聚合的方法就地涂敷于容器壁。碳氟聚合物膜可被吹入MDI容器成袋状物。可用做膜材的有许多种碳氟聚合物例如ETFE,FEP,和PTFE。
适合的固化温度依赖于涂敷所选用的碳氟聚合物/聚合物掺配物及涂敷方法。但是,对于盘管涂敷和喷涂通常需要温度超过聚合物的融点,例如,超过融点大约50℃并维持至多达大约20分钟,例如大约5~10分钟,例如大约8分钟或按需要定。上述提到的优选的和特别优选的碳氟聚合物/聚合物掺配物的固化温度在大约300℃~大约400℃,例如大约350℃~380℃是合适的。对于等离子聚合所要求的通常温度大约是20℃~大约100℃。
碳氟聚合物也可用碳氟化合物单体等离子聚合的方法就地涂敷于容器壁。碳氟聚合物膜可被吹入MDI容器内成袋状物。有许多种碳氟聚合物例如ETFE,FEP和PTFE适合用做膜材。
采用本领域的方法(例如,参见Byron,如上述,和美国专利5,345,980)可以用来制备此处提及的MDI’s,这些方法中用传统的容器代替那些氟代聚合物涂敷的容器。即,二丙酸氯地米松及制剂的其它成分填充入涂有氟代聚合物的一种气雾剂容器。容器上配有一种阀盖部件,将阀盖弯边就位。药物在流体形式的碳氟化合物抛射剂中的混悬液可通过定量阀施放,参见美国专利5,345,980在此引入作为参考。
此处提到的内部涂敷碳氟化合物的MDI’s可以按现在临床使用的无涂敷MDI’s类似的方式用于临床。但是,此处提到的MDI’s特别适用于含有和施放下述吸入药物制剂,该制剂使用氢氟烷碳氟化合物抛射剂例如134a并且很少、或者基本上没有赋形剂,它倾向于沉积或粘着于MDI系统的内壁或部件上。在某些情况下,施放一种基本上不含赋形剂的吸入药物是有利的,例如,当病人可能对赋形剂敏感或者药物与赋形剂发生反应时。
包括上述制剂的MDI’s,MDI系统和这种用于治疗有关呼吸疾病例如哮喘的MDI系统包括本发明的又一方面。
很明显,对于本领域的技术人员来说,在不偏离本发明的精神的情况下,可很容易修改上述发明。此处提及的所有发明主题,包括任何这种修改,要求受到保护。
下面的非限定性实例用以帮助说明本发明。
实施例
例1
标准12.5ml MDI容器(Presspart Inc.,Cary,NC)用底漆(DuPont851-204)按卖主的标准程序喷涂(Livingstone Coatings,Charlotte,NC)并固化,然后再一次用FEP或者PFA(DuPont 856-200和857-200,分别地)喷涂,再按卖主的标准程序固化。涂敷的厚度大约为10μm~50μm。然后除去这些容器中的空气(参见PCT申请号WO94/22722(PCT/EP94/00921))使阀门弯边就位,将大约24mg二丙酸氯地米松与大约18gm P134a的混悬液从阀门灌入。
例2
标准0.46mm厚铝片(联合铝)用FEP(DuPont 856-200)喷涂(DuPont,Wilmington,DE)并固化。然后这些片材被拉制成容器(Presspart Inc.,Cary,NC),涂敷的厚度大约为10μm~50μm。清除这些容器中的空气,使阀门弯边就位,将大约60mg二丙酸氯地米松与大约18gm P134A的混悬液从阀门灌入。
例3
标准12.5ml MDI容器(Presspart Inc.,Cary,NC)用PTFE-PES掺配物(DuPont)按卖主的标准程序涂敷成单一涂层然后固化。涂敷的厚度在大约1μm~大约20μm之间。清除这些容器中的空气,使阀门弯边就位,将大约溶于大约6.1mg水和大约18.2g P134a的微粉化二丙酸氯地米松一水合物68mg混悬液从阀门灌入。
例4
标准12.5ml MDI容器(Presspart Inc.,Cary,NC)用PTFE-FEP-聚酰胺酰亚胺掺配物(DuPont)按卖主的标准程序喷涂,然后固化。涂敷的厚度在大约1μm~大约20μm之间。清除容器中的空气,使阀门弯边就位,将溶于大约6.1mg水与大约18.2g P134a大约68mg微粉化二丙酸氯地米松一水合物的混悬液从阀门灌入。
例5
标准12.5ml MDI容器(Presspart Inc.,Cary,NC)用一种静电枪喷涂FEP粉末(DuPont FEP 532)。涂敷的厚度在大约1μm~大约20μm之间。清除容器中的空气,使阀门弯边就位,将溶于大约6.1mg水与大约18.2g P134a的大约68mg微粉化二丙酸氯地米松一水合物混悬液从阀门灌入。
例6
标准0.46mm厚铝片用FEP-苯并胍胺喷涂然后固化。然后将这些铝片拉制成容器。清除容器中的空气,使阀门弯边就位,将溶于大约6.1mg水和约18.2g P134a中的大约68mg微粉化二丙酸氯地米松一水合物的混悬液从阀门灌入。
例7
标准12.5ml MDI容器(Presspart Inc.,Cary,NC)用PFA(HoechstPFA-6900n)的一种含水分散体喷涂并固化。涂敷的厚度在大约1μm~大约20μm之间。清除这些容器中的空气,使阀门弯边就位,然后将溶于大约6.1mg水与大约18.2g P134a中的大约68mg微粉化二丙酸氯地米松-水合物的混悬液从阀门灌入。
例8
标准12.5ml MDI容器(Presspart Inc.,Cary,NC)用PTFE-PES掺配物(DuPont)按照卖主的标准程序喷涂成单一涂层并固化。涂敷的厚度在大约1μm~大约20μm之间。清除这些容器中的空气,使阀门弯边就位,然后将溶于大约182mg乙醇与大约18.2g P134a的大约68mg微粉化二丙酸氯地米松-水合物的混悬液从阀门灌入。
例9
标准12.5ml MDI容器(Presspart Inc.,Cary,NC)用PTFE-FEP-聚酰胺酰亚胺掺配物(DuPont)按照卖主的标准程序喷涂并固化。涂敷的厚度在大约1μm~大约20μm之间。清除这些容器中的空气。使阀门弯边就位,然后将溶于大约182mg的乙醇与大约18.2gP134a的大约68mg微粉化二丙酸氯地米松-水合物的混悬液从阀门灌入。
例10
标准12.5ml MDI容器(Presspart Inc.,Cary,NC)用一种静电枪喷涂FEP粉末(DuPont FEP 532)涂敷的厚度在大约1μm~大约20μm之间。清除这些容器中的空气。使阀门弯边就位,将溶于大约182mg乙醇和大约18.2g P134a的大约68mg微粉化二丙酸氯地米松一水合物从阀门灌入。
例11
标准厚度为0.46mm的铝片用FEP-苯并胍胺喷涂并固化。将这些铝片拉制成容器。清除罐中的空气,使阀门弯边就位,将溶于大约182mg乙醇与大约18.2g P134a的大约68mg微粉化二丙酸氯地米松一水合物的混悬液从阀门灌入。
例12
标准12.5ml MDI容器(Presspart Inc.,Cary,NC)用PFA(HoechstPFA-6900n)的一种含水分散体喷涂并固化。涂敷的厚度在大约1μm~大约20μm之间。清除这些容器中的空气。使阀门弯边就位,将溶于大约182mg乙醇与大约18.2g P134a的大约68mg微粉化二丙酸氯地米松一水合物的混悬液从阀门灌入。
例13
标准12.5ml MDI容器(Presspart Inc.,Cary,NC)用PTFE-PES掺配物(DuPont)按照卖主的标准程序涂敷成单一涂层并固化。涂敷的厚度在大约1μm~大约20μm之间。清除这些容器中的空气。使阀门弯边就位,将溶于大约107mg乙醇与大约21.4gP227中的大约13.6mg微粉化二丙酸氯地米松的混悬液从阀门灌入。
例14
标准12.5ml MDI容器(Presspart Inc.,Cary,NC)用PTFE-FEP-聚酰胺酰亚胺掺配物(DuPont)按照卖主的标准程序喷涂并固化。涂敷的厚度在大约1μm~大约20μm之间。清除这些容器中的空气,使阀门弯边就位,然后将溶于大约107mg乙醇与大约21.4g P227中的大约13.6mg微粉化二丙酸氯地米松的混悬液从阀门灌入。
例15
标准12.5ml MDI容器(Presspart Inc.,Cary,NC)用一种静电枪喷涂FEP粉末(DuPont FEP 532)。涂敷的厚度在大约1μm~大约20μm之间。清除容器中的空气。使阀门弯边就位,然后将溶于大约107mg乙醇与大约21.4g P227中的大约13.6mg微粉化二丙酸氯地米松的混悬液从阀门灌入。
例16
标准0.46mm厚的铝片用FEP-苯并胍胺喷涂并固化。将这种铝片拉制成容器。清除容器中的空气。使阀门弯边就位,将溶于大约107mg乙醇与大约21.4g P227的大约13.6mg微粉化二丙酸氯地米松的混悬液从阀门灌入。
例17
标准12.5ml MDI容器(Presspart Inc.,Cary,NC)用PFA(HoechstPFA-6900n)的一种含水分散体喷涂并固化。涂敷的厚度在大约1μm~大约20μm之间。清除容器中的空气。使阀门弯边就位,然后将溶于大约107mg乙醇与大约21.4gP227的大约13.6mg微粉化二丙酸氯地米松的混悬液从阀门灌入。
例18-22
重复例3~例7的步骤,只是将大约24mg舒喘灵游离碱或同等重量的盐例如硫酸盐,和大约12mg二丙酸氯地米松一水合物混合于大约364mg乙醇和大约18.2g P134a中,并从阀门灌入。
例23-42
重复例3~例22的步骤,只是使用经改进的有基本上呈椭圆形底的12.5ml MDI容器。
我们发现,在模拟的使用条件下,从被测试的这种MDIs的药物施放是恒定的,比较来看,对照用MDIs是灌入未涂敷的容器中,在使用过程中,药物施放却有着显著地降低。
Claims (21)
1.一种计定剂量吸入器,它的部分或全部内表面用一种或多种碳氟聚合物,任意地与一种或多种非碳氟聚合物共同涂敷,用来施放一种吸入药物制剂,制剂中包括二丙酸氯地米松或者它的一种生理可接受的溶剂化物,一种碳氟化合物抛射剂,任意地与一种或多种其它药理活性剂或者一种或多种赋形剂共同混合。
2.权利要求1的吸入器,包括该药物制剂。
3.权利要求2的吸入器,其中该药物制剂进一步包括一种表面活性剂。
4.权利要求2或者权利要求3的吸入器,其中该药物制剂进一步包括一种极性共溶剂。
5.权利要求2的吸入器,其中该药物制剂包括一种极性共溶剂,其占抛射剂重量的0.01~5%,w/w,该制剂基本不含表面活性剂。
6.权利要求4或者权利要求5的吸入器,其中这种极性共溶剂是乙醇。
7.权利要求2至6中的任何一种吸入器,其中该药物制剂包括二丙酸氯地米松或者其一种生理可接受溶剂化物与沙美特罗(Salmeterol)或者舒喘灵或者其一种生理可接受盐共同混合。
8.权利要求2的吸入器,其中该药物制剂包括
(a)二丙酸氯地米松一水合物,基本上所有一水合物的粒径小于20μm;
(b)除一水合物所带结晶水的水分外,制剂中的水分重量至少占制剂总重量的0.15%;和
(c)一种碳氟化合物抛射剂。
9.权利要求8的吸入器,其中制剂中进一步包括一种极性共溶剂,其占抛射剂的量的0.05~3%w/w。
10.权利要求9的吸入器,其中极性共溶剂是乙醇。
11.权利要求2的吸入器,其中该药物制剂基本上包括二丙酸氯地米松或者其一种生理可接受溶剂化物,任意地与一种或多种其它药理活性剂,一种碳氟化合物抛射剂和一种占抛射剂量0.01~5%w/w的极性共溶剂共同混合,该制剂基本不含有表面活性剂。
12.权利要求2至11中的任何一种吸入器,其中碳氟化合物抛射剂是1,1,1,2-四氟乙烷或者1,1,1,2,3,3,3-七氟-n-丙烷或者它们的混合物。
13.权利要求12的吸入器,其中碳氟化合物抛射剂是1,1,1,2-四氟乙烷。
14.权利要求1至13中的任何一种吸入器,包括一种由金属制成的容器,其中部分或者全部金属内表面被涂敷。
15.权利要求14的吸入器,其中金属是铝或者其合金。
16.权利要求1至15中的任何一种吸入器,其中所说的碳氟聚合物是一种全氟碳聚合物。
17.权利要求16的吸入器,其中该碳氟聚合物由PTFE,PFA,FEP和它们的混合物中选择。
18.权利要求1至17中的任何一种吸入器,其中该碳氟聚合物与一种由聚酰胺酰亚胺和聚醚砜中选出的非碳氟聚合物共同混和。
19.权利要求1~权利要求18中的任何一种吸入器,包括一种基本上椭圆形的底。
20.一种计定剂量吸入器系统,包括权利要求1至19中的任何一种吸入器,配有口腔或鼻腔吸入药物制剂适用的引导装置。
21.权利要求20的计定剂量吸入器系统在治疗呼吸疾病中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42228095A | 1995-04-14 | 1995-04-14 | |
US08/422,280 | 1995-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1186473A true CN1186473A (zh) | 1998-07-01 |
Family
ID=23674168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96194409A Pending CN1186473A (zh) | 1995-04-14 | 1996-04-11 | 二丙酸氯地米松计定剂量吸入器 |
Country Status (26)
Country | Link |
---|---|
US (3) | US6149892A (zh) |
EP (1) | EP0820414B1 (zh) |
JP (1) | JP3573213B2 (zh) |
KR (1) | KR19980703850A (zh) |
CN (1) | CN1186473A (zh) |
AP (1) | AP835A (zh) |
AT (1) | ATE258813T1 (zh) |
AU (1) | AU718851B2 (zh) |
BG (1) | BG102023A (zh) |
BR (1) | BR9604979A (zh) |
CA (1) | CA2218179A1 (zh) |
CZ (1) | CZ326197A3 (zh) |
DE (1) | DE69631476T2 (zh) |
EA (1) | EA000889B1 (zh) |
EE (1) | EE9700372A (zh) |
ES (1) | ES2214536T3 (zh) |
GE (1) | GEP20002266B (zh) |
HU (1) | HUP9800641A3 (zh) |
IS (1) | IS4581A (zh) |
NO (1) | NO974738L (zh) |
NZ (1) | NZ306281A (zh) |
OA (1) | OA10625A (zh) |
PL (1) | PL180880B1 (zh) |
SK (1) | SK139197A3 (zh) |
TR (1) | TR199701170T1 (zh) |
WO (1) | WO1996032345A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101909684B (zh) * | 2007-11-06 | 2014-03-19 | 3M创新有限公司 | 药物吸入装置及其部件 |
CN110840864A (zh) * | 2019-12-20 | 2020-02-28 | 广州健康元呼吸药物工程技术有限公司 | 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品 |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4003270A1 (de) * | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgase und ihre verwendung in arzneimittelzubereitungen |
TR199701168T1 (xx) * | 1995-04-14 | 1998-05-21 | Glaxo Wellcome Inc. | Flutikazon Propionat i�in �l��lm�� doz inhaleri. |
HUP9800641A3 (en) * | 1995-04-14 | 2001-04-28 | Glaxo Wellcome Inc Res Triangl | Metered dose inhaler for beclomethasone dipropionate |
ES2206572T3 (es) * | 1995-04-14 | 2004-05-16 | Smithkline Beecham Corporation | Inhalador de dosis medida para salmeterol. |
GB9526392D0 (en) | 1995-12-22 | 1996-02-21 | Glaxo Group Ltd | Medicaments |
GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
US6413496B1 (en) | 1996-12-04 | 2002-07-02 | Biogland Ireland (R&D) Limited | Pharmaceutical compositions and devices for their administration |
IES80485B2 (en) * | 1996-12-04 | 1998-08-12 | Bioglan Ireland R & D Ltd | Pharmaceutical compositions and devices for their administration |
CA2282845A1 (en) * | 1997-03-18 | 1998-09-24 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US6054487A (en) * | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US6120752A (en) * | 1997-05-21 | 2000-09-19 | 3M Innovative Properties Company | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
US20010031244A1 (en) * | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
GB2338951B (en) * | 1997-09-03 | 2000-06-21 | Bespak Plc | Improvements in or relating to metering valves for pressuriseddispensing containers |
US20030103906A1 (en) * | 1997-10-14 | 2003-06-05 | Smithkline Beecham Corporation | Metered dose inhaler having internal surfaces coated with fluorocarbon polymer |
GB9814717D0 (en) * | 1998-02-23 | 1998-09-02 | Bespak Plc | Improvements in drug delivery devices |
MXPA00008174A (es) * | 1998-02-23 | 2004-03-10 | Glaxo Group Ltd | Mejoras en los dispositivos de distribucion de medicamento. |
AU753921B2 (en) * | 1998-02-23 | 2002-10-31 | Glaxo Group Limited | Improvements in drug delivery devices |
GB9805938D0 (en) | 1998-03-19 | 1998-05-13 | Glaxo Group Ltd | Valve for aerosol container |
WO1999055600A1 (en) * | 1998-04-30 | 1999-11-04 | 3M Innovative Properties Company | Metered-dose valve for pharmaceutical aerosol |
GB2340759B (en) * | 1998-08-26 | 2003-05-07 | Bespak Plc | Improvements in drug delivery devices |
DZ2947A1 (fr) * | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
EP1169244B1 (en) | 1999-03-12 | 2005-11-02 | Glaxo Group Limited | Metering valve |
US6315985B1 (en) | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
IT1313553B1 (it) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
IT1317720B1 (it) * | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
DE10004465A1 (de) * | 2000-02-02 | 2001-08-16 | Pari Gmbh | Inhalationsvernebler |
IT1317846B1 (it) * | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
WO2001064182A2 (en) | 2000-02-28 | 2001-09-07 | Vectura Limited | Improvements in or relating to the delivery of oral drugs |
AU2001256168A1 (en) * | 2000-03-01 | 2001-09-12 | Glaxo Group Limited | Metered dose inhaler |
WO2001064273A2 (en) * | 2000-03-01 | 2001-09-07 | Glaxo Group Limited | Metered dose inhaler |
JP2003525091A (ja) * | 2000-03-01 | 2003-08-26 | グラクソ グループ リミテッド | 定量噴霧式吸入器 |
US20030145850A1 (en) * | 2000-03-01 | 2003-08-07 | Hailey Mark Andrew | Metered dose inhaler |
IT1318514B1 (it) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. |
ME00220B (me) * | 2000-05-22 | 2010-10-10 | Chiesi Farm Spa | Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom |
WO2001089616A1 (en) * | 2000-05-23 | 2001-11-29 | Glaxo Group Limited | Aerosol container for formulations of salmeterol xinafoate |
AU2001270074A1 (en) | 2000-06-22 | 2002-01-02 | Glaxo Group Limited | Method and package for storing a pressurized container containing a drug |
GB0016876D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Novel formulation |
AU2001284158B2 (en) * | 2000-08-18 | 2004-03-25 | Norton Healthcare, Ltd. | Spray device |
WO2002024552A2 (en) | 2000-09-18 | 2002-03-28 | Glaxo Group Limited | Coated can for a metered dose inhaler |
GB2367756B (en) | 2000-10-12 | 2003-01-08 | Bespak Plc | Dispensing apparatus |
SE0004610D0 (sv) | 2000-12-13 | 2000-12-13 | Astrazeneca Ab | Surface modification process |
PL204659B1 (pl) | 2000-12-22 | 2010-01-29 | Glaxo Group Ltd | Pojemnik do inhalatora dozującego |
GB2375098B (en) | 2001-04-30 | 2003-08-27 | Bespak Plc | Improvements in valves for pressurised dispensing containers |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
ES2222294T3 (es) | 2001-07-02 | 2005-02-01 | Chiesi Farmaceutici S.P.A. | Formulacion optimizada de tobramicina para administracion en forma de aerosol. |
GB0122725D0 (en) * | 2001-09-21 | 2001-11-14 | Glaxo Group Ltd | Drug dispensing components |
GB2384190A (en) | 2002-01-22 | 2003-07-23 | Bespak Plc | Dispensing device for a powdered product |
SE0200313D0 (sv) * | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel process |
US20040126325A1 (en) * | 2002-03-12 | 2004-07-01 | David Lewis | Medicinal aerosol solution formulation products with improved chemical stability |
EP1565256A4 (en) * | 2002-09-13 | 2008-05-07 | Glaxo Group Ltd | COATED MIXING DEVICE |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
JP2006511297A (ja) * | 2002-12-18 | 2006-04-06 | グラクソ グループ リミテッド | ベント型マウスピースを有する投薬システム |
ME00420B (me) * | 2003-03-20 | 2011-12-20 | Boehringer Ingelheim Pharmaceuticals Inc | Formulacija, za inhalator u kojem se odmjerava doza, u kojoj se kao propelenti koriste hidro-fluoro-alkani |
US20040191176A1 (en) * | 2003-03-28 | 2004-09-30 | Kaplan Leonard W | Formulations for treatment of pulmonary disorders |
ATE494239T1 (de) * | 2003-06-24 | 2011-01-15 | Cipla Ltd | Vorrichtung zum abgeben von pharmazeutischen produkten |
EP1654312B1 (en) | 2003-08-11 | 2014-01-15 | Glaxo Group Limited | Pharmaceutical metered dose inhaler and methods relating thereto |
MXPA06002075A (es) | 2003-08-29 | 2006-05-19 | Glaxo Group Ltd | Inhalador de dosis farmaceutica medida y metodos relacionados. |
WO2005044187A2 (en) * | 2003-10-28 | 2005-05-19 | Glaxo Group Limited | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
FR2872494B1 (fr) * | 2004-07-01 | 2006-11-17 | Valois Sas | Distributeur de produits fluide ou pulverisant |
CA2571519C (en) * | 2004-07-02 | 2013-05-14 | Boehringer Ingelheim International Gmbh | Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant |
EP1848444B1 (en) * | 2005-02-10 | 2016-11-09 | Glaxo Group Limited | Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom |
US20090029901A1 (en) * | 2005-02-10 | 2009-01-29 | Marian Wood-Kaczmar | Process for Crystallizing Lactose Particles for Use in Pharmaceutical Formulations |
DE102006017320A1 (de) * | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel |
JP5825757B2 (ja) | 2007-02-11 | 2015-12-02 | マップ・ファーマシューティカルズ・インコーポレイテッド | 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 |
WO2008112661A2 (en) | 2007-03-09 | 2008-09-18 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
GB0721739D0 (en) | 2007-11-06 | 2007-12-19 | 3M Innovative Properties Co | medicinal inhalation devices and components thereof |
GB0721737D0 (en) | 2007-11-06 | 2007-12-19 | 3M Innovative Properties Co | Medicinal inhalation devices and components thereof |
US8227027B2 (en) | 2007-12-07 | 2012-07-24 | Presspart Gmbh & Co. Kg | Method for applying a polymer coating to an internal surface of a container |
EP2320878B1 (de) | 2008-09-04 | 2015-02-25 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH | Monoterpene für die behandlung von atemwegserkrankungen, insbesondere bronchopulmonalen erkrankungen |
GB2456028A (en) * | 2008-11-14 | 2009-07-01 | Consort Medical Plc | A medicament dispenser with an HFO propellant |
EP2427591A1 (en) | 2009-05-06 | 2012-03-14 | 3M Innovative Properties Company | Medicinal inhalation device |
US10410838B2 (en) | 2009-05-06 | 2019-09-10 | 3M Innovative Properties Company | Apparatus and method for plasma treatment of containers |
EP2427278B1 (en) | 2009-05-06 | 2015-09-23 | 3M Innovative Properties Company | Medicinal inhalation devices and components thereof |
DK2501363T3 (en) | 2009-11-17 | 2015-03-23 | Cipla Ltd | inhalable |
US10231948B2 (en) | 2017-02-27 | 2019-03-19 | Jason Ty Nguyen | Metered dose inhaler compositions, systems, and methods |
US11779716B2 (en) * | 2017-08-03 | 2023-10-10 | Kindeva Drug Delivery L.P. | Method for making medicinal delivery device having multi-layer coating |
GB201717996D0 (en) | 2017-10-31 | 2017-12-13 | Portal Medical Ltd | Medicament dispenser device |
CN115087431A (zh) * | 2020-02-20 | 2022-09-20 | 奇斯药制品公司 | 包含缓冲药物制剂的加压定量吸入器 |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT12188B (zh) | 1901-04-18 | 1903-06-10 | William Chapman | |
US2562118A (en) * | 1950-02-09 | 1951-07-24 | Du Pont | Polytetrafluoroethylene coating compositions |
NL95166C (zh) * | 1954-09-20 | |||
US2968427A (en) * | 1955-06-28 | 1961-01-17 | Meshberg Philip | Valve for aerosol container |
GB878409A (en) * | 1957-03-26 | 1961-09-27 | United Drug And Chemical Compa | Improvements in or relating to dispensing devices |
US2886217A (en) * | 1957-05-20 | 1959-05-12 | Riker Laboratories Inc | Dispensing device |
US2892576A (en) * | 1957-11-14 | 1959-06-30 | Lawrence T Ward | Metering button valve assembly |
US2980301A (en) * | 1958-09-02 | 1961-04-18 | Riker Laboratories Inc | Metering valve for aerosol container |
GB864392A (en) * | 1958-11-10 | 1961-04-06 | Rexall Drug Company Ltd | Improvements in or relating to dispensing devices for aerosols |
US3506737A (en) | 1965-10-23 | 1970-04-14 | Owens Illinois Inc | Glass aerosol bottles and method for making same |
GB1191700A (en) | 1967-02-27 | 1970-05-13 | Ekco Prod Inc | Coated Metalware |
US3505737A (en) * | 1967-10-02 | 1970-04-14 | Theodore L Merolla | Fluid substitution device |
FR1584784A (zh) * | 1968-08-13 | 1970-01-02 | ||
FR2082593A5 (en) | 1970-03-20 | 1971-12-10 | Oreal | Aerosol can prodn |
NO134730L (zh) | 1971-07-19 | 1900-01-01 | ||
LU63737A1 (zh) | 1971-08-17 | 1972-01-04 | ||
US3896602A (en) * | 1971-09-15 | 1975-07-29 | Tor H Petterson | Method of manufacturing of a barrier package |
US4087026A (en) * | 1971-09-15 | 1978-05-02 | Petterson Tor H | Barrier package |
FR2159593A5 (fr) * | 1971-11-04 | 1973-06-22 | Skm Sa | Installation de peinture par pulverisation |
US4143204A (en) * | 1971-12-27 | 1979-03-06 | E. I. Du Pont De Nemours And Company | Articles coated with fluorocarbon resins |
DE2227142A1 (de) * | 1972-06-03 | 1973-12-13 | Pampus Kg | Rohre und behaelter aus glasfaserverstaerktem kunststoff und einer auskleidung, zum beispiel aus ptfe |
US3962171A (en) * | 1973-03-02 | 1976-06-08 | Mcgarry & Waters | Composition for protecting surfaces |
US3929537A (en) * | 1973-07-19 | 1975-12-30 | Austral Erwin Engineering Co | Preparation of plastic-metal laminates |
FR2267496A1 (en) * | 1974-04-11 | 1975-11-07 | Sidel Sa | Method of sealing valve on aerosol container - uses internally ribbed sleeve over ribbed valve and sleeve |
US4180609A (en) * | 1975-07-11 | 1979-12-25 | E. I. Du Pont De Nemours And Company | Article coated with fluoropolymer finish with improved scratch resistance |
NL7709408A (nl) | 1976-08-26 | 1978-02-28 | Union Carbide Corp | Aerosolhouders van kunststof en werkwijze ter vervaardiging daarvan. |
GB2003415A (en) | 1977-09-02 | 1979-03-14 | American Can Co | Improvements relating to the manufacture of containers |
US4125152A (en) * | 1977-09-19 | 1978-11-14 | Borg-Warner Corporation | Scale resistant heat transfer surfaces and a method for their preparation |
JPS5920547B2 (ja) * | 1979-07-04 | 1984-05-14 | 東洋製罐株式会社 | 溶接缶 |
DE2947025A1 (de) * | 1979-11-22 | 1981-06-04 | Glyco-Metall-Werke Daelen & Loos Gmbh, 6200 Wiesbaden | Zwei- oder mehrschicht-verbundwerkstoff |
ZA807387B (en) * | 1979-12-08 | 1981-11-25 | Metal Box Co Ltd | Containers |
CA1201114A (en) * | 1980-02-15 | 1986-02-25 | Gordon H. Phillipps | Androstane carbothioates |
GB2077229B (en) * | 1980-05-16 | 1983-08-03 | Neotechnic Eng Ltd | Valve assembly for a pressurized aerosoldispensing container |
GB2105189B (en) | 1981-07-24 | 1985-03-20 | Fisons Plc | Inhalation drugs |
ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US4487878A (en) * | 1983-06-30 | 1984-12-11 | E. I. Du Pont De Nemours And Company | Coating composition of a solution fluorocarbon polymer, a dispersed fluorocarbon polymer and a polyamine curing agent |
EP0199487B1 (en) * | 1985-04-19 | 1991-03-06 | Nippon Steel Corporation | Cans and a method for making cans |
NL8501767A (nl) * | 1985-06-19 | 1987-01-16 | Euro Technical Oilservices Bv | Inrichting voor het behandelen van een verontreinigingen bevattende vloeistof. |
EP0234774B1 (en) * | 1986-02-27 | 1992-05-06 | Nippon Kokan Kabushiki Kaisha | Precoating metal sheet |
JPS6312445A (ja) * | 1986-06-24 | 1988-01-19 | 東洋製罐株式会社 | イ−ジイオ−プン蓋付缶体及びその製法 |
US4897439A (en) * | 1986-07-01 | 1990-01-30 | Edlon Products, Inc. | Polymer-metal bonded composite and method of producing same |
US5536583A (en) * | 1986-07-01 | 1996-07-16 | Edlon Products, Inc. | Polymer metal bonded composite and method of producing same |
EP0260084B1 (en) * | 1986-09-08 | 1992-12-30 | Asia Can Company Limited | Metal container and method of manufacturing the same |
US4819834A (en) * | 1986-09-09 | 1989-04-11 | Minnesota Mining And Manufacturing Company | Apparatus and methods for delivering a predetermined amount of a pressurized fluid |
GB2205297B (en) * | 1987-06-05 | 1991-06-19 | Lin Pac Mouldings | A container assembly |
JP2612758B2 (ja) * | 1987-06-26 | 1997-05-21 | ヴエルデイング,ヴインフリート・ジヤン | 加圧下にある製品の貯蔵及び排出制御のための装置 |
DE8709978U1 (de) * | 1987-07-21 | 1987-10-08 | A. u. K. Müller GmbH & Co KG, 4000 Düsseldorf | Elektromagnetventil, insbesondere Auslaufventil für Brühwasser |
GB8724243D0 (en) * | 1987-10-15 | 1987-11-18 | Metal Box Plc | Laminates of polyolefin-based film |
GB8724242D0 (en) * | 1987-10-15 | 1987-11-18 | Metal Box Plc | Laminated metal sheet |
IT1223451B (it) * | 1987-11-24 | 1990-09-19 | Coster Tecnologie Speciali Spa | Procedimento per ottenere fondelli metallici protetti per valvole per aerosol e simili |
GB2214891A (en) | 1988-02-05 | 1989-09-13 | Fibrenyle Ltd | Containers for pressurized material |
GB2216794B (en) * | 1988-03-22 | 1991-11-20 | Fisons Plc | Pharmaceuticals compositions |
FI94342C (fi) * | 1988-03-29 | 1995-08-25 | Ciba Geigy Ag | Menetelmä uusien alkanofenonien valmistamiseksi |
JPH0289633A (ja) | 1988-05-20 | 1990-03-29 | Sumitomo Electric Ind Ltd | フッ素樹脂被覆物 |
US4961966A (en) * | 1988-05-25 | 1990-10-09 | The United States Of America As Represented By The Administrator Of The Environmental Protection Agency | Fluorocarbon coating method |
US4902318A (en) * | 1988-05-25 | 1990-02-20 | The United States Of America As Represented By The Administrator Of The Environmental Protection Agency | Inlet apparatus for gas-aerosol sampling |
GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
GB8903629D0 (en) * | 1989-02-17 | 1989-04-05 | Metal Box Plc | Metal/polymer laminates |
US5176132A (en) * | 1989-05-31 | 1993-01-05 | Fisons Plc | Medicament inhalation device and formulation |
US5006383A (en) * | 1989-06-28 | 1991-04-09 | The Dow Chemical Company | Polymeric blend and laminated structures prepared therefrom |
FR2650219B1 (fr) * | 1989-07-06 | 1991-10-04 | Pechiney Rhenalu | Procede d'obtention de materiaux multicouches aptes a etre transformes par emboutissage ou emboutissage-etirage en corps creux |
FR2649359B1 (fr) * | 1989-07-06 | 1993-02-12 | Cebal | Bande ou portion de bande pour emboutissage ou emboutissage-etirage, et son utilisation |
US4972037A (en) * | 1989-08-07 | 1990-11-20 | Minnesota Mining And Manufacturing Company | Polysiloxane-grafted copolymer topical binder composition with novel fluorochemical comonomer and method of coating therewith |
US5208226A (en) * | 1989-09-08 | 1993-05-04 | Glaxo Group Limited | Medicaments |
US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
US5345980A (en) * | 1989-09-21 | 1994-09-13 | Glaxo Group Limited | Method and apparatus an aerosol container |
US5043191A (en) * | 1990-02-27 | 1991-08-27 | Miles Inc. | Method of protecting hard surfaces |
DE4009397A1 (de) * | 1990-03-23 | 1991-09-26 | Weidenhammer Packungen | Dosenartige verpackung fuer fliessfaehige produkte |
US5192548A (en) * | 1990-04-30 | 1993-03-09 | Riker Laboratoires, Inc. | Device |
AU614234B1 (en) * | 1990-06-28 | 1991-08-22 | Kabushiki Gaisha Tokai | Vessel for aerosol |
DE4023909A1 (de) * | 1990-07-27 | 1992-01-30 | Wild Rudolf Gmbh & Co | Wiederverwendbarer behaelter aus kunststoff sowie seine herstellung und verwendung |
GB9024365D0 (en) * | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
EP0487200B1 (en) * | 1990-11-14 | 2000-06-21 | Titeflex Corporation | Fluoropolymer aluminium laminate |
DE69116170T2 (de) * | 1990-12-12 | 1996-08-29 | E.I. Du Pont De Nemours & Co., Wilmington, Del. | Nichthaftendes beschichtungssystem mit ptfa und pfa oder fep für konzentrationsgradienten |
US5168107A (en) * | 1990-12-12 | 1992-12-01 | E. I. Du Pont De Nemours And Company | Non-stick coating system with PTFE of two low melt viscosities for concentration gradient |
WO1992010549A1 (en) * | 1990-12-12 | 1992-06-25 | E.I. Du Pont De Nemours And Company | Non-stick coating system with ptfe of different melt viscosities for concentration gradient |
GB9027234D0 (en) * | 1990-12-15 | 1991-02-06 | Harris Pharma Ltd | An inhalation device |
EP0499142A3 (en) * | 1991-02-09 | 1993-05-05 | Hoechst Aktiengesellschaft | Potentiation of the antireactive-antiasthmatic effect of inhaled loop diuretics by inhaled non steroidal anti-flammatory drugs |
EP0504112A3 (en) * | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
RU2027448C1 (ru) | 1991-04-25 | 1995-01-27 | Государственное предприятие "ВЭЛТ" | Ингалятор |
RU2008939C1 (ru) | 1991-06-10 | 1994-03-15 | Вячеслав Николаевич Поздняков | Физиотерапевтический ингалятор |
RU2012362C1 (ru) | 1991-06-24 | 1994-05-15 | Юрий Алексеевич Волгин | Ингалятор |
DE4124730C3 (de) * | 1991-07-25 | 2001-09-06 | Ahc Oberflaechentechnik Gmbh | Anodisierte Gegenstände aus Aluminium oder Magnesium mit in die Oxidschicht eingelagerten Fluorpolymeren und Verfahren zu deren Herstellung |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
US5736124A (en) * | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
US5653962A (en) * | 1991-12-12 | 1997-08-05 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
US5202110A (en) * | 1992-01-22 | 1993-04-13 | Virginia Commonwealth University | Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants |
US5261538A (en) * | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
DE69334088T2 (de) * | 1992-06-25 | 2007-06-21 | Denso Corp., Kariya | System zum Identifizieren beweglicher Objekte |
US5376359A (en) * | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
MX9304585A (es) * | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata. |
US5250356A (en) * | 1992-08-28 | 1993-10-05 | E. I. Du Pont De Nemours And Company | Cookware coating system |
IT1263783B (it) * | 1993-01-21 | 1996-08-29 | Claudio Bignami | Formulazioni di prodotti vernicianti per rivestimenti antiaderenti, applicabili mediante rullatura a dischi di alluminio non decapati utilizzabili per lo stampaggio di pentolame domestico |
US5411771A (en) * | 1993-04-29 | 1995-05-02 | Tsai; Tung-Hung | Method for coating metal cookware |
JP3093525B2 (ja) | 1993-07-02 | 2000-10-03 | 九州日本電気株式会社 | 半導体集積回路 |
US6596260B1 (en) * | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
US5421492A (en) * | 1993-11-02 | 1995-06-06 | Glaxo Inc. | Metered aerosol dispensing apparatus and method of use thereof |
FR2713299B1 (fr) * | 1993-12-01 | 1996-02-16 | Joint Francais | Piston étanche et aérosol comportant un tel piston. |
US5468798A (en) * | 1994-02-18 | 1995-11-21 | Whitford Corporation | Basecoat for a coating system |
US5447600A (en) * | 1994-03-21 | 1995-09-05 | Texas Instruments | Polymeric coatings for micromechanical devices |
US5508023A (en) * | 1994-04-11 | 1996-04-16 | The Center For Innovative Technology | Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant |
US5597433A (en) * | 1994-05-27 | 1997-01-28 | Panoramic, Inc. | Method and apparatus for manufacturing plastic canisters |
DE4434425C2 (de) * | 1994-09-27 | 1997-04-03 | Fissler Gmbh | Verfahren zur Erzeugung einer Antihaftbeschichtung sowie mit einer solchen versehene Gegenstände |
DE19500726C2 (de) * | 1995-01-12 | 1998-07-02 | Fraunhofer Ges Forschung | Vorrichtung zur Dosierung kleinster Pulvermengen zur Erzeugung eines Aerosols |
TR199701168T1 (xx) * | 1995-04-14 | 1998-05-21 | Glaxo Wellcome Inc. | Flutikazon Propionat i�in �l��lm�� doz inhaleri. |
HUP9800641A3 (en) * | 1995-04-14 | 2001-04-28 | Glaxo Wellcome Inc Res Triangl | Metered dose inhaler for beclomethasone dipropionate |
EE03997B1 (et) * | 1995-04-14 | 2003-04-15 | Glaxo Wellcome Inc. | Albuterooli doseeriv inhalaator |
ES2206572T3 (es) * | 1995-04-14 | 2004-05-16 | Smithkline Beecham Corporation | Inhalador de dosis medida para salmeterol. |
US5674592A (en) * | 1995-05-04 | 1997-10-07 | Minnesota Mining And Manufacturing Company | Functionalized nanostructured films |
US5891420A (en) * | 1997-04-21 | 1999-04-06 | Aeropharm Technology Limited | Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation |
-
1996
- 1996-04-11 HU HU9800641A patent/HUP9800641A3/hu unknown
- 1996-04-11 JP JP53118196A patent/JP3573213B2/ja not_active Expired - Fee Related
- 1996-04-11 PL PL96322781A patent/PL180880B1/pl unknown
- 1996-04-11 AP APAP/P/1997/001112A patent/AP835A/en active
- 1996-04-11 US US08/945,141 patent/US6149892A/en not_active Expired - Fee Related
- 1996-04-11 CA CA002218179A patent/CA2218179A1/en not_active Abandoned
- 1996-04-11 DE DE1996631476 patent/DE69631476T2/de not_active Revoked
- 1996-04-11 KR KR1019970707250A patent/KR19980703850A/ko not_active Application Discontinuation
- 1996-04-11 AU AU54812/96A patent/AU718851B2/en not_active Ceased
- 1996-04-11 BR BR9604979A patent/BR9604979A/pt not_active Application Discontinuation
- 1996-04-11 GE GEAP19963926A patent/GEP20002266B/en unknown
- 1996-04-11 WO PCT/US1996/005009 patent/WO1996032345A1/en not_active Application Discontinuation
- 1996-04-11 AT AT96911713T patent/ATE258813T1/de not_active IP Right Cessation
- 1996-04-11 EA EA199700230A patent/EA000889B1/ru not_active IP Right Cessation
- 1996-04-11 CN CN96194409A patent/CN1186473A/zh active Pending
- 1996-04-11 ES ES96911713T patent/ES2214536T3/es not_active Expired - Lifetime
- 1996-04-11 SK SK1391-97A patent/SK139197A3/sk unknown
- 1996-04-11 NZ NZ306281A patent/NZ306281A/xx unknown
- 1996-04-11 EP EP96911713A patent/EP0820414B1/en not_active Revoked
- 1996-04-11 EE EE9700372A patent/EE9700372A/xx unknown
- 1996-04-11 TR TR97/01170T patent/TR199701170T1/xx unknown
- 1996-04-11 CZ CZ973261A patent/CZ326197A3/cs unknown
-
1997
- 1997-10-07 IS IS4581A patent/IS4581A/is unknown
- 1997-10-10 OA OA70103A patent/OA10625A/en unknown
- 1997-10-13 NO NO974738A patent/NO974738L/no not_active Application Discontinuation
- 1997-11-05 BG BG102023A patent/BG102023A/xx unknown
-
2000
- 2000-02-18 US US09/506,838 patent/US6511653B1/en not_active Expired - Fee Related
- 2000-02-18 US US09/506,834 patent/US6511652B1/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101909684B (zh) * | 2007-11-06 | 2014-03-19 | 3M创新有限公司 | 药物吸入装置及其部件 |
CN110840864A (zh) * | 2019-12-20 | 2020-02-28 | 广州健康元呼吸药物工程技术有限公司 | 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品 |
CN110840864B (zh) * | 2019-12-20 | 2022-02-22 | 广州健康元呼吸药物工程技术有限公司 | 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1186473A (zh) | 二丙酸氯地米松计定剂量吸入器 | |
CN1142798C (zh) | 沙美特罗的计定剂量吸入器 | |
CN1113675C (zh) | 丙酸福地卡松的计定剂量吸入器 | |
CN1217654C (zh) | 舒喘宁的计定剂量吸入器 | |
JP2003525090A (ja) | 定量噴霧式吸入器 | |
US20040223919A1 (en) | Metered dose inhaler having internal surfaces coated with fluorocarbon polymer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1009426 Country of ref document: HK |